Financial Survey: Global Wholehealth Partners (OTCMKTS:GWHP) and ZimVie (NASDAQ:ZIMV)

ZimVie (NASDAQ:ZIMV) and Global Wholehealth Partners (OTCMKTS:GWHP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Valuation & Earnings

This table compares ZimVie and Global Wholehealth Partners”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZimVie	$449.75 million	1.19	-$25.83 million	($0.70)	-27.13
Global Wholehealth Partners	N/A	N/A	N/A	N/A	N/A

Global Wholehealth Partners has lower revenue, but higher earnings than ZimVie.

Profitability

This table compares ZimVie and Global Wholehealth Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZimVie	-4.39%	6.37%	3.34%
Global Wholehealth Partners	N/A	N/A	N/A

Institutional & Insider Ownership

95.6% of ZimVie shares are held by institutional investors. 5.4% of ZimVie shares are held by insiders. Comparatively, 10.3% of Global Wholehealth Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ZimVie and Global Wholehealth Partners, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZimVie	1	4	0	0	1.80
Global Wholehealth Partners	0	0	0	0	0.00

ZimVie currently has a consensus price target of $17.75, indicating a potential downside of 6.53%. Given Global Wholehealth Partners’ higher probable upside, analysts clearly believe Global Wholehealth Partners is more favorable than ZimVie.

Summary

ZimVie beats Global Wholehealth Partners on 5 of the 8 factors compared between the two stocks.

About ZimVie

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.

About Global Wholehealth Partners

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.